REPRIEVE EU - Randomized Trial to Prevent Vascular Events in HIV

A phase III study evaluating the effect of Pitavastatin to prevent cardiovascular events in HIV-1 infected individuals

NEAT ID EU5332

EUDRACTNumber: 2018-001285-41

CO-SPONSORS:

NEAT ID Foundation & Massachusetts  General Hospital 

Indication: HIV-infected patients on ART considered at low to moderate risk for cardiovascular disease and without a history of cardiovascular disease

 

Countries: Spain

 

Status: Active

Administrative office: NEAT ID Foundation, 27 Old Gloucester Street, London WC1N 3AX, UK

     e: NEAT-ID@NEAT-ID.org     

w: www.NEAT-ID.org

Registered address: PL 709  Rue Haute 322, 1000 Brussels, Belgium

©NEAT ID 2019